| Jun 24 |
Takeda gets Japan nod for first post-transplant anti-CMV treatment
|
| Jun 24 |
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
|
| Jun 24 |
Takeda reports positive data from Phase IIb trial of ITP treatment
|
| Jun 24 |
EC approves Takeda’s Fruzaqla for metastatic colorectal cancer
|
| Jun 24 |
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
|
| Jun 23 |
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
|
| Jun 21 |
Takeda gets EU approval for Fruzaqla for colorectal cancer
|
| Jun 21 |
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
|
| Jun 21 |
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
|
| Jun 21 |
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
|
